NCT01847924View on ClinicalTrials.gov

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Cognitive Impairment
Interventions
DRUG

MLC901

24 weeks intervention with orally MLC901. 2 capsules 3 times a day

DRUG

Placebo

24 weeks intervention with orally placebo. 2 capsules 3 times a day

Trial Locations (5)

1015

University of Santo Tomas Hospital, Manila

119074

National University Hospital, Singapore

169608

Singapore General Hospital, Singapore

308433

National Neuroscience Institute, Singapore

Unknown

National Geriatric Hospital, Hanoi

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT01847924 - NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects | Biotech Hunter | Biotech Hunter